Establishment Labs Holdings (ESTA) Liabilities and Shareholders Equity (2017 - 2026)
Establishment Labs Holdings' (ESTA) quarterly Liabilities and Shareholders Equity came in at $351.0 million in Q1 2026, up 5.3% year-on-year from $333.4 million in Q1 2025, and down 1.72% quarter-over-quarter from $357.2 million in Q4 2025.
Establishment Labs Holdings (ESTA) Liabilities and Shareholders Equity (2017 - 2026) Analysis & Trends
Establishment Labs Holdings' Liabilities and Shareholders Equity history runs 10 years deep, the most recent figure standing at $351.0 million for Q1 2026.
- On a quarterly basis, Liabilities and Shareholders Equity rose 5.3% year-over-year to $351.0 million in Q1 2026; TTM through Mar 2026 was $1.4 billion, a 10.32% increase from a year earlier, with the FY2025 full-year figure at $357.2 million, up 2.98% from the prior year.
- Liabilities and Shareholders Equity declined to $351.0 million in Q1 2026 per ESTA's latest filing, from $357.2 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $357.2 million in Q4 2025 and bottomed at $141.6 million in Q1 2022.
- The 5-year median for Liabilities and Shareholders Equity is $285.1 million (2024), against an average of $276.5 million.
- Biggest YoY gain for Liabilities and Shareholders Equity was 51.27% in 2022; the steepest drop was 7.08% in 2022.
- Year by year, Liabilities and Shareholders Equity stood at $211.1 million in 2022, then rose by 27.28% to $268.6 million in 2023, then increased by 29.11% to $346.8 million in 2024, then gained by 2.98% to $357.2 million in 2025, then retreated by 1.72% to $351.0 million in 2026.
- Per Business Quant, the three latest ESTA Liabilities and Shareholders Equity figures stand at $351.0 million (Q1 2026), $357.2 million (Q4 2025), and $338.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | 110.43 Bn |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 46.29 Bn |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 93.03 Bn |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 44.35 Bn |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | 13.32 Bn |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 6.63 Bn |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 31.92 Bn |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | 37.13 Bn |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | 10.46 Bn |
| 10 | Establishment Labs Holdings | 2.73 Bn | 2.66 Bn | 42.34 Mn | 351.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 351.04 Mn |
| Dec 31, 2025 | 357.17 Mn |
| Sep 30, 2025 | 338.90 Mn |
| Jun 30, 2025 | 329.67 Mn |
| Mar 31, 2025 | 333.36 Mn |
| Dec 31, 2024 | 346.83 Mn |
| Sep 30, 2024 | 282.69 Mn |
| Jun 30, 2024 | 285.09 Mn |
| Mar 31, 2024 | 301.84 Mn |
| Dec 31, 2023 | 268.64 Mn |
| Sep 30, 2023 | 270.53 Mn |
| Jun 30, 2023 | 285.30 Mn |
| Mar 31, 2023 | 209.36 Mn |
| Dec 31, 2022 | 211.06 Mn |
| Sep 30, 2022 | 187.65 Mn |
| Jun 30, 2022 | 199.88 Mn |
| Mar 31, 2022 | 141.56 Mn |
| Dec 31, 2021 | 139.53 Mn |
| Sep 30, 2021 | 148.36 Mn |
| Jun 30, 2021 | 152.12 Mn |